Novartis AG ADR (NVS)vsTandem Diabetes Care Inc (TNDM)
NVS
Novartis AG ADR
$153.81
-0.54%
HEALTHCARE · Cap: $288.85B
TNDM
Tandem Diabetes Care Inc
$21.43
+0.14%
HEALTHCARE · Cap: $1.49B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 5344% more annual revenue ($56.69B vs $1.04B). NVS leads profitability with a 22.5% profit margin vs -6.1%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
TNDM
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-71.8%
Fair Value
$93.10
Current Price
$153.81
$60.71 premium
Intrinsic value data unavailable for TNDM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
No standout strengths identified
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Trading at 11.4x book value
Smaller company, higher risk/reward
Weak financial health signals
ROE of -71.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : TNDM
TNDM has a balanced fundamental profile.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : TNDM
The primary concerns for TNDM are Price/Book, Market Cap, Piotroski F-Score. Debt-to-equity of 5.67 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a value stock while TNDM is a turnaround play — different risk/reward profiles.
TNDM carries more volatility with a beta of 1.54 — expect wider price swings.
TNDM is growing revenue faster at 5.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 28/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Tandem Diabetes Care Inc
HEALTHCARE · MEDICAL DEVICES · USA
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and markets various products for people with insulin-dependent diabetes in the United States. The company is headquartered in San Diego, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?